Thank you Mirrors of Medicine & dear Colleagues
#PROSCA24 #BLADDR24 & #RENALC24
FINAL STATS with OVER 21 million impression on X
SHOUT OUT TO Our Ambassadors Specially
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@pgrivasmdphd.bsky.social
@achoud72.bsky.social
Thank you Mirrors of Medicine & dear Colleagues
#PROSCA24 #BLADDR24 & #RENALC24 have just concluded with OVER 20 million impression on X
SHOUT OUT TO Our Ambassadors
Specially
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@pgrivasmdphd.bsky.social
@achoud72.bsky.social
GREAT 1st DAY OF #PROSCA24
Currently going on in Vienna🇦🇹
Perfect way to follow up 2 Amazing meetings in #RENALC24 @ #BLADDR24 w/ OVER 10 million impressions on X ‼️
Kudos to Mirrors of Medicine
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
OVER 6 Million Impressions for #BLADDR24
THANK YOU, our Colleagues!
JOIN US TOMORROW for Day 1 #PROSCA24
STRONG SoMe Internationally
🇺🇸🇬🇧🇮🇹🇲🇽🇨🇭🇫🇷🇯🇵🇹🇷
WE ARE @OncoAlert 🚨
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day Two of #BLADDR24
Presenter: Dr Ananya Choudhury
Case discussion session: metastatic UCa
Histological subtypes in the metastatic setting: what now?
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day 2 of #BLADDR24
Dr Rob Jones
Case metastatic UCa
Treatment sequencing in the era of combination therapies
Emphasizes that first-line therapy with EV and P is poised to become the new SoC
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day Two of #BLADDR24
Presenter: Dr. Dora Niedersüß-Beke
Case discussion session: metastatic UCa
Do real-world data confirm trial data of the new SOC in first line?
More Real World Data needed!
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day Two of #BLADDR24
Presenter: Dr Daniele Raggi
Are ADCs a better partner for IO than platinum-based chemotherapy in met UCA
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day Two of #BLADDR24
Dr Rob Jones
BCa management 2025
Medical oncologist View
New options in perioperative systemic therapy
New challenges in metastatic
NMIBC:Tsunami for medical oncologists
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day Two of #BLADDR24
Dr Vérane Achard
BCa management in 2025
View of the radiation oncologist
Radiotherapy is no longer just an alternative to surgery but a key component
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day Two of #BLADDR24
Presenter: Dr Kilian Gust
Looking ahead: BCa management in 2025
View of the Urologists
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day Two of #BLADDR24
Dr Ben-Max de Ruiter
The optimal TURBT
outlines essential strategies for achieving accurate pathological diagnosis, staging, and complete removal of visible lesions in TaT1 bladder cancer (BC).
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@achoud72.bsky.social
Day 2 of #BLADDR24
Dr Fred Witjes
Practical aspects of intravesical instillation
importance of following general instillation principles, including adequate hydration. Quinolones are highlighted as a sensible option for managing BCG Side effects
@drnataliagandur.bsky.social
@achoud72.bsky.social
To early to conclude. The CON of prof Witjes was quite convincing in my opinion #bladdr24
7% more DSS
Day 1 of #BLADDR24
Dr. Petros Grivas
The concept of withholding radical treatment, such as radical cystectomy (RC) or radiotherapy, for patients with a clinical complete response (cCR) after neoadjuvant or induction systemic therapy is emerging as a potential future approach in #BladderCancer MGt
#WhereisHoskin appears on #BlueSky How to further personalise #radiotherapy
➡️ Bladder only unless N+
➡️ Give NAC if appropriate
➡️ Use a radiosensitiser, any radiosensitiser
➡️ There are compelling biomarkers, but need prospective qualification
#BLADDR24 @oncoalert.bsky.social
Day One of #BLADDR24
Dr Gunhild von Amsberg
Presentation on first-line treatment for advanced urothelial carcinoma highlights the need to balance efficacy, safety, patient characteristics,& QoL.
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day 1 of #BLADDR24
Dr Celena Scheede-Bergdahl
RC & neobladder
Prehabilitation programme
Prehabilitation in cancer care takes place between diagnosis & start of acute tx, focusing on physical & psychological assessments
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@achoud72.bsky.social
Great discussion, but what about #radiotherapy We will be asking this question in the #TRAIN trial #BLADDR24 @oncoalert.bsky.social
in NIAGARA Adding perioperative durvalumab (DURVA) to neoadjuvant gemcitabine and cisplatin (GC) significantly improves event-free survival (EFS) and overall survival (OS) in patients, without causing delays in radical cystectomy (RC).
#BLADDR24
Great discussion, but what about #radiotherapy? #BLADDR24 @oncoalert.bsky.social
Despite the promise of AI, there is still no validated biomarker for predicting resistance to BCG or response to neoadjuvant chemotherapy (NAC), and much validation work is needed before AI can be fully integrated into clinical practice.
#BLADDR24
AI shows promise in predicting the outcomes of intravesical therapy by analyzing TURBT histology combined with clinical data & automated performance metrics could enhance surgical skills for TURBT procedures. Overall, AI is making significant strides in optimizing NMIBC treatment decisions #BLADDR24
Day One of #BLADDR24
Dr. Ben-Max de Ruiter
High-risk BCG-naive NMIBC: should we stick to BCG?
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day 1 of #BLADDR24
Dr Kilian Gust
Debate: Are we ready to de-intensify treatment and surveillance in low-grade NMIBC?
CON
While de-intensification and surveillance in low-grade NMIBC may be appealing, it is premature
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@achoud72.bsky.social
Day One of #BLADDR24
Dr Cédric Lebâcle
Debate: Are we ready to de-intensify treatment and surveillance in low-grade NMIBC?
"pro" side: adapted de-intensification strategy offers several benefits.
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day One of #BLADDR24
Dr Petros Grivas
Debate: Role of ctDNA to manage MIBC in the adjuvant setting #BladderCancer
Presentation discusses if TOMBOLA is practice changing, and more data is needed
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day One of #BLADDR24
Dr Maria De Santis
MIBC ESMO congress highlights #BladderCancer
Perioperative durvalumab to neoadj gemcitabine & cisplatin improves EFS & OS, w/o delays in radical cystectomy
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
#BLADDR24 #ESMO24 highlights
➡️ Adj CKI post cystectomy
➡️ SUNRISE IV - can neoadjuvant non-platinum treatment be used?
➡️ Trials of perioperative combos
@oncoalert.bsky.social
Day One of #BLADDR24
Dr Eva Maria Compérat
Role of AI for diagnosis and monitoring #BladderCancer
Emphasizes the broad potential of AI in diagnosing and monitoring
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
